Nuo Therapeutics, Inc. (OTCMKTS:NUOTQ) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security
Holders.
On April 28, 2017, Nuo Therapeutics, Inc. (the Company) filed
with the Securities and Exchange Commission a Definitive Schedule
14A Consent Solicitation Statement (the Consent Solicitation) and
thereafter mailed the Consent Solicitation to the Companys
stockholders of record as of April 25, 2017 (the Record Date).
The Consent Solicitation solicited written consents of the
Companys stockholders approving and authorizing an amendment (the
Amendment) to the Companys second amended and restated
certificate of incorporation for the purposes of effecting a
reverse stock split (the Reverse Split) of the Companys
outstanding common stock, par value $0.0001 per share (the Common
Stock), at a specific ratio (the Reverse Ratio) within a range
from 1-for-2 to 1-for-4 and to authorize the Companys Board of
Directors to determine, in its discretion, the timing of the
Amendment and the specific Reverse Ratio, so long as the Reverse
Split is effected at any time prior to December 31, 2017.
As of the Record Date, the Company had 9,927,112 shares of Common
Stock and 29,038 shares of its Series A preferred stock, par
value $0.0001 per share (the Series A Preferred Stock), issued
and outstanding. Accordingly, the votes or written consents of
stockholders holding at least 4,963,557 shares of the issued and
outstanding Common Stock, or at least 4,818,367 shares of the
issued and outstanding Common Stock and all 29,038 shares of the
issued and outstanding Series A Preferred Stock, were necessary
to approve the Amendment.
As of May 5, 2017, the Company received the written consent of
more than a majority of the voting power of its capital stock
outstanding as of the Record Date in favor of the Amendment and
terminated the Consent Solicitation period.
The final vote tabulation on the Amendment prior to termination
of the Consent Solicitation period was as follows:
| Consent (For) | Consent Withheld (Against) | Abstain | |
| 5,077,201 | 0 |
On May 8, 2017, the Company issued a press release announcing the
stockholders approval of the Reverse Split, which is attached
hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit Number |
Description |
| 99.1 | Press Release of Nuo Therapeutics, Inc., dated May 8, 2017 |
About Nuo Therapeutics, Inc. (OTCMKTS:NUOTQ)
Nuo Therapeutics, Inc., formerly Cytomedix, Inc., is a regenerative therapies company developing and marketing products within the United States and internationally through its strategic partners. The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company’s commercial offerings are centered on its point of care platform technologies for the separation of blood and bone marrow to produce platelet based therapies or cell concentrates. It is promoting two distinct platelet rich plasma (PRP) technologies: the Aurix System for wound care, and the Angel concentrated Platelet Rich Plasma (cPRP) System for orthopedics and cardiovascular markets. The Company is focused on developing product candidates utilizing the Bright Cell technology platform, owned by its subsidiary, Aldagen, Inc. Nuo Therapeutics, Inc. (OTCMKTS:NUOTQ) Recent Trading Information
Nuo Therapeutics, Inc. (OTCMKTS:NUOTQ) closed its last trading session at 0.0120 with shares trading hands.
